Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Short Interest Up 45.1% in September

Key Points

• Tonix Pharmaceuticals saw a 45.1% increase in short interest in September, bringing the total to approximately 1.93 million shares, which accounts for about 22.0% of the company's total shares.
• The company's stock is currently trading at $18.88, significantly down from its 12-month high of $130.00, with a market cap of $165.58 million.
• Recent earnings reports indicated a quarterly loss of ($3.86) EPS, missing analysts' expectations, and the firm is forecasted to have a net margin of negative 828.22% for the current year.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report) saw a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling 1,930,000 shares, an increase of 45.1% from the September 15th total of 1,330,000 shares. Approximately 22.0% of the shares of the company are sold short. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 1.3 days. Based on an average daily volume of 1,520,000 shares, the short-interest ratio is presently 1.3 days. Approximately 22.0% of the shares of the company are sold short.

Tonix Pharmaceuticals Trading Down 4.2%

Shares of TNXP stock opened at $18.88 on Thursday. Tonix Pharmaceuticals has a 12 month low of $6.76 and a 12 month high of $130.00. The stock has a market cap of $165.58 million, a P/E ratio of -0.48 and a beta of 1.87. The company has a 50 day simple moving average of $27.74 and a two-hundred day simple moving average of $30.72.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($3.86) EPS for the quarter, missing analysts' consensus estimates of ($3.10) by ($0.76). Tonix Pharmaceuticals had a negative net margin of 828.22% and a negative return on equity of 57.93%. The business had revenue of $2.00 million for the quarter, compared to analysts' expectations of $2.60 million. As a group, equities analysts forecast that Tonix Pharmaceuticals will post -1762.5 earnings per share for the current year.

Institutional Trading of Tonix Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $25,000. Ameritas Investment Partners Inc. purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $62,000. BNP Paribas Financial Markets purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $65,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Tonix Pharmaceuticals in the second quarter worth $104,000. 82.26% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on TNXP shares. Weiss Ratings restated a "sell (e+)" rating on shares of Tonix Pharmaceuticals in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Tonix Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Tonix Pharmaceuticals presently has an average rating of "Hold" and an average target price of $70.00.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.